123 related articles for article (PubMed ID: 29593397)
1. In vitro analysis of PARP inhibitor nanoformulations.
Baldwin P; Tangutoori S; Sridhar S
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):59-61. PubMed ID: 29593397
[TBL] [Abstract][Full Text] [Related]
2. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
3. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
4. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Gonzales J; Kossatz S; Roberts S; Pirovano G; Brand C; Pérez-Medina C; Donabedian P; de la Cruz MJ; Mulder WJM; Reiner T
Bioconjug Chem; 2018 Nov; 29(11):3776-3782. PubMed ID: 30354077
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?
Perego G; Nozza R; Oggionni E; Cabiddu M; Scolari C; Omati E; Castelli EA; Petrelli F
J Oncol Pharm Pract; 2020 Jun; 26(4):967-971. PubMed ID: 32041467
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
8. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
[TBL] [Abstract][Full Text] [Related]
10. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
12. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
[TBL] [Abstract][Full Text] [Related]
13. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
14. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes
van de Ven AL; Tangutoori S; Baldwin P; Qiao J; Gharagouzloo C; Seitzer N; Clohessy JG; Makrigiorgos GM; Cormack R; Pandolfi PP; Sridhar S
Mol Cancer Ther; 2017 Jul; 16(7):1279-1289. PubMed ID: 28500233
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
17. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Plummer R; Verheul HM; De Vos FYFL; Leunen K; Molife LR; Rolfo C; Grundtvig-Sørensen P; De Grève J; Rottey S; Jerusalem G; Italiano A; Spicer J; Dirix L; Goessl C; Birkett J; Spencer S; Learoyd M; Bailey C; Dean E
Adv Ther; 2018 Nov; 35(11):1945-1964. PubMed ID: 30324586
[TBL] [Abstract][Full Text] [Related]
20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
